Valuation: CureVac

Market Cap 867M 986M 807M 741M 1.39B 94.57B 1.41B 9.59B 3.75B 46.69B 3.7B 3.62B 161B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 424M 482M 395M 363M 681M 46.26B 690M 4.69B 1.83B 22.84B 1.81B 1.77B 78.96B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2023-03-27
Chief Tech/Sci/R&D Officer 60 -
Chief Operating Officer 61 2021-06-30
Director TitleAgeSince
Chairman 75 2015-07-31
Director/Board Member 58 2015-07-31
Director/Board Member 69 2022-06-21

Financials

2026 *2027 *
Net sales - -
Net income -132M -151M -123M -113M -213M -14.44B -215M -1.47B -572M -7.13B -565M -553M -24.65B -
Net Debt - -
Logo CureVac
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Employees
904
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB